ARMATA PHARMACEUTICALS, INC. Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost
ARMATA PHARMACEUTICALS, INC. (ARMP) had Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost of $1.93 million as of 2025-12-31, per its 10-K filed 2026-03-25.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost · last filed 2026-03-25
- 2025-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $1.93M.
- 2024-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $1.80M.
- 2023-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $2.08M; Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost as first filed $2.08K.
- 2022-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $3.19K; Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost as first filed $3.19M.
| Period end | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost as first filed |
|---|---|---|
| 2025-12-31 | $1.93M 10-K · filed 2026-03-25 | |
| 2024-12-31 | $1.80M 10-K · filed 2026-03-25 | |
| 2023-12-31 | $2.08M 10-K · filed 2025-03-21 | $2.08K 10-K · filed 2024-03-21 |
| 2022-12-31 | $3.19K 10-K · filed 2024-03-21 | $3.19M 10-K · filed 2023-03-16 |
| 2021-12-31 | $2.47M 10-K · filed 2023-03-16 | |
| 2020-12-31 | $2.09M 10-K · filed 2022-03-17 | |
| 2019-12-31 | $1.36M 10-K · filed 2021-03-18 | |
| 2018-12-31 | $934.00K 10-K · filed 2020-03-19 | $272.00K 10-K · filed 2019-03-25 |
| 2017-12-31 | $188.00K 10-K · filed 2019-03-25 | |
| 2016-12-31 | $795.00K 10-K · filed 2018-03-14 | $1.01M 10-K · filed 2017-03-27 |
| 2015-12-31 | $479.00K 10-K · filed 2017-03-27 | |
| 2014-12-31 | $1.38M 10-K · filed 2016-03-30 | |
| 2013-12-31 | $1.12M 10-K · filed 2015-04-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |